WASHINGTON, DC - (NewMediaWire) - October 20, 2015 - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in cannabis formulation-based drug development, today announced that the noted and highly credentialed New York cardiovascular surgeon, long time advocate for Africa and the African Diaspora, health and social activist, and the son of the legendary Pan-Africanist, Marcus Garvey, Dr. Julius Garvey, has been appointed to the Scientific Advisory Board and the International Government Affairs Board of CBIS.
Dr. Garvey was born in Jamaica, spent some of his formative years in England, received his undergraduate and medical degrees from McGill University, and trained in surgery and cardiovascular surgery in New York and Baltimore. He has worked as an Associate Professor of Surgery at Albert Einstein College of Medicine in Bronx, NY, Assistant Professor of Surgery, State University of NY at Stony Brook, NY, as well as Instructor in Surgery at Columbia University College of Physicians & Surgeons, NY. Additionally, his hospital appointments are expansive. He has been an Attending Cardiothoracic Surgeon at Harlem Hospital Center in NY, NY and Montefiore Hospital in Bronx, NY, Associate Attending Head of Thoracic Surgery at the Montefiore Morrisania Affiliate in Bronx, NY, and Acting Program Director in the Division of Cardiothoracic Surgery at Long Island Jewish Medical Center in New Hyde Park, NY. He was also Chief of Vascular & Thoracic Surgery at Queens Hospital Center and is presently an attending surgeon on staff of the Long Island Jewish Medical Center.
Dr. Garvey is a renowned activist and has followed in the footsteps of his celebrated father, Marcus Garvey. He is an advocate who believes that although Africans and those in the African Diaspora have come a long way since the days of the United Negro Improvement Association founded in 1914 by his father, the civil rights movement of the 1940s, 50s, and 60s, and the ending of formal colonialism on the African continent, that there is still much to be done to achieve real political and economic freedom for those of African descent. Dr. Garvey's decision to become a physician grew out of the ideals of his family.
"My father dedicated his life to the service of people and the people that he chose were his own race," Dr. Garvey has said. "It was a matter of which service I'd choose." Dr. Garvey has traveled widely on the African continent and across the countries of the African Diaspora and has real-world and academic knowledge of the health and health care problems facing peoples of African descent.
"Dr. Garvey brings his extraordinary vision and intimate medical knowledge to our human family. As a physician with a practice of wide demographic diversity Dr. Garvey understands the everyday problems, the health, and healthcare issues of a diverse population. This significantly brings all our drug development programs another level of expert progress and procedures. His vast medical experience and understanding of local, state, and national health issues accelerates our mission to bring our formal drugs to market," stated Mr. Raymond Dabney, President and CEO of Cannabis Science.
Dr. Garvey is a Fellow of the Royal College of Surgeons (Canada), the American College of Surgeons, The American College of Phlebology, the International College of Surgeons, and the American College of Chest Physicians. In addition, he is a Diplomat of the Board of Cardiothoracic & Vascular Surgery, the American Board of Surgery, and the American Academy of Wound Management. Dr. Garvey's exposure and expertise in vascular surgery, cardiovascular surgery, phlebology, and wound care leads his determination to comprehensively address the concerns of all patients seen at Garvey Vascular Specialists afflicted with vascular disorders. After his training, he returned to New York in 1970 where he held several appointments at hospitals in New York, including acting program director of cardiothoracic surgery at Long Island Jewish Medical Center. He has also taught at several universities in New York and continues as an associate professor of surgery at State University of New York at Stony Brook. In 1983 he entered private practice on Long Island.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.